The FDA Group's Insider Newsletter
Subscribe
Sign in
Home
Notes
Archive
Leaderboard
About
Latest
Top
Discussions
GMP Compliance in 503B Compounding Pharmacies: Navigating the Challenges with Jesse Gillikan
A conversation with Jesse Gillikan, President & CEO of cGMP Validation, on the evolving landscape of GMP compliance for compounding pharmacies.
May 20
•
The FDA Group
Share this post
The FDA Group's Insider Newsletter
GMP Compliance in 503B Compounding Pharmacies: Navigating the Challenges with Jesse Gillikan
Copy link
Facebook
Email
Notes
More
24:23
RA/QA News Roll: Mid May 2025
Here's what's happening at FDA and across the broader life science RA/QA space.
May 15
•
The FDA Group
Share this post
The FDA Group's Insider Newsletter
RA/QA News Roll: Mid May 2025
Copy link
Facebook
Email
Notes
More
The FDA Plans to Roll Out AI for Reviews This Summer — Here's What to Know
The agency just set an "aggressive timeline" for AI Implementation after a successful pilot. Here's what to start thinking about now.
May 14
•
The FDA Group
2
Share this post
The FDA Group's Insider Newsletter
The FDA Plans to Roll Out AI for Reviews This Summer — Here's What to Know
Copy link
Facebook
Email
Notes
More
Tracking Major Changes at the FDA: May 13
Policy shifts, AI rollouts, reappointments, and legal backlash.
May 13
•
The FDA Group
1
Share this post
The FDA Group's Insider Newsletter
Tracking Major Changes at the FDA: May 13
Copy link
Facebook
Email
Notes
More
Unannounced FDA Foreign Inspections Expand as Administration Pushes Domestic Manufacturing
Domestic manufacturing is about to get fast-tracked while foreign facilities face surprise inspections. Are you ready?
May 7
•
The FDA Group
3
Share this post
The FDA Group's Insider Newsletter
Unannounced FDA Foreign Inspections Expand as Administration Pushes Domestic Manufacturing
Copy link
Facebook
Email
Notes
More
RA/QA News Roll: Late April 2025
Here's what's happening at FDA and across the broader life science RA/QA space.
May 1
•
The FDA Group
3
Share this post
The FDA Group's Insider Newsletter
RA/QA News Roll: Late April 2025
Copy link
Facebook
Email
Notes
More
April 2025
A Closer Look at the Common Prereview Medical Device Compliance Pitfalls an FDA Panel Cited at MedCon
How to avoid compliance issues around software change documentation, design creep, and marketing beyond intended use
Apr 29
•
The FDA Group
5
Share this post
The FDA Group's Insider Newsletter
A Closer Look at the Common Prereview Medical Device Compliance Pitfalls an FDA Panel Cited at MedCon
Copy link
Facebook
Email
Notes
More
Tracking Major Changes at the FDA: April 25
The agency faces database setbacks, leadership changes, and legal challenges as staff cuts reshape regulation and enforcement.
Apr 25
•
The FDA Group
7
Share this post
The FDA Group's Insider Newsletter
Tracking Major Changes at the FDA: April 25
Copy link
Facebook
Email
Notes
More
FDA Warning Letter Breakdown: Quality Systems Fail at a Medical Device Manufacturer
A long list of deficiencies offers a ton of lessons for device firms on what the FDA is finding and citing.
Apr 24
•
The FDA Group
10
Share this post
The FDA Group's Insider Newsletter
FDA Warning Letter Breakdown: Quality Systems Fail at a Medical Device Manufacturer
Copy link
Facebook
Email
Notes
More
The ICH Just Released Its Overhauled Stability Guideline for Consultation
Here's a detailed breakdown plus a few questions for self-assessment.
Apr 22
•
The FDA Group
6
Share this post
The FDA Group's Insider Newsletter
The ICH Just Released Its Overhauled Stability Guideline for Consultation
Copy link
Facebook
Email
Notes
More
15 Audit Questions That Could Save You From an FDA Warning Letter (Part 3)
In our final installment, we explore five overlooked—but frequently cited—compliance risks drawn from recent FDA enforcement actions.
Apr 21
•
The FDA Group
7
Share this post
The FDA Group's Insider Newsletter
15 Audit Questions That Could Save You From an FDA Warning Letter (Part 3)
Copy link
Facebook
Email
Notes
More
Tracking Major Changes at the FDA: April 18
A leaked HHS budget reveals major FDA cuts, layoffs delay pediatric policy meeting, and biotech firms report review slowdowns.
Apr 18
•
The FDA Group
Share this post
The FDA Group's Insider Newsletter
Tracking Major Changes at the FDA: April 18
Copy link
Facebook
Email
Notes
More
Share
Copy link
Facebook
Email
Notes
More
This site requires JavaScript to run correctly. Please
turn on JavaScript
or unblock scripts